2021 CTAD Presentation

2021 CTAD Presentation:

 

Phase 1 trial design for ACU193, a monoclonal antibody that selectively binds soluble Aβ oligomers.

File Type: pdf
File Size: 1 MB
Categories: 2021
Tags: 2021, CTAD, INTERCEPT-AD, Presentation, Trial Design, TwentyTwentyOne